Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions
Lihua Wu,Chang Xu,Guolan Wu,Huili Zhou,Duo Lv,You Zhai,Yujie Huang,Wenling Tang,Fangqiong Li,Jianzhong Shentu
DOI: https://doi.org/10.2147/DDDT.S207561
2019-11-25
Abstract:Lihua Wu, 1, 2, * Chang Xu, 1, 2, * Guolan Wu, 1, 2 Huili Zhou, 1, 2 Duo Lv, 1, 2 You Zhai, 1, 2 Yujie Huang, 1, 2 Wenling Tang, 3 Fangqiong Li, 4 Jianzhong Shentu 1–3 1 Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 2 Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 3 College of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 4 Clinical Research Department, Haisco Pharmaceutical Group, Sichuan, People's Republic of China *These authors contributed equally to this work Correspondence: Jianzhong Shentu Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, People's Republic of China Tel +86 571 87236560 Fax +86 571 87214223 Email stjz@zju.edu.cn Purpose: A fixed-dose combination (FDC) tablet of melitracen/flupentixol has been widely used for depression. The purpose of this study was to assess the safety profile and the relative bioavailability of two FDC products containing 10 mg melitracen and 0.5 mg flupentixol from two different manufacturers, in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. Methods: The study was designed as a single-dose, randomized, open-label, 2-period crossover study under fasted or fed conditions in healthy Chinese subjects. Twenty-four subjects (16 men and 8 women) were selected for fasted study, and another 24 cases (16 men and 8 women) were in fed study. Each subject was randomized at the beginning to receive either a single dose of the reference FDC or the test FDC tablet during the first period. Following two-week washout period, all subjects received the alternate formulation during the second period. Blood samples were collected up to 144 hrs after administration. Pharmacokinetic parameters, including C max , T max , AUC 0-t , AUC 0-∞ , t1⁄2, CL/F, and V d /F were acquired based on the time versus concentration profiles. Then, the geometric mean ratios (GMR) and corresponding 90% CIs were calculated for the determination of bioequivalence analysis. Safety assessment included changes in vital signs and laboratory tests, physical examination findings, and incidence or reports of adverse events (AEs). Results: The present study has clearly indicated the test and the reference FDC products are bioequivalent in terms of rate and extent of drug absorption. GMR of C max , AUC 0–t , and AUC 0-∞ for both flupentixol and melitracen between the two formulation FDC products, and corresponding 90% CIs, were all within the range of 80% to 125% under fasted or fed conditions. Both the test and the reference FDC products indicated good tolerance in all volunteers. Chinese Clinical Trials Registry identifier: CTR20171256. Keywords: bioequivalence, melitracen, flupentixol, pharmacokinetics, fixed-dose combination tablet